NEOFLOW TECHNOLOGIES LTD

NeoFlow is aiming to make a widely accessible simple design endovascular device for the treatment of vasospasm. The Vasoconstriction relief should be achieved by a humble local manipulation, reducing the angioplasty and systemic pharmacology risks.

The general incidence of aSAH stands at 9.2/100,000 worldwide. Nearly half of the aSAH patients will suffer from symptomatic vasospasm, and approximately 2/3 of the vasospasm patients will require active intervention to treat the acute symptoms. The vasospasm complication direct hospitalization costs the US health system stands on 1.5B USD in total, which is on average an additional 40K USD per patient.

David Skorohod - CEO & Co-Founder